Barrios-Bernal, P.; Zatarain-Barrón, Z.L.; Hernández-Pedro, N.; Orozco-Morales, M.; Olivera-Ramírez, A.; Ávila-Moreno, F.; Colín-González, A.L.; Cardona, A.F.; Rosell, R.; Arrieta, O.
Will We Unlock the Benefit of Metformin for Patients with Lung Cancer? Lessons from Current Evidence and New Hypotheses. Pharmaceuticals 2022, 15, 786.
https://doi.org/10.3390/ph15070786
AMA Style
Barrios-Bernal P, Zatarain-Barrón ZL, Hernández-Pedro N, Orozco-Morales M, Olivera-Ramírez A, Ávila-Moreno F, Colín-González AL, Cardona AF, Rosell R, Arrieta O.
Will We Unlock the Benefit of Metformin for Patients with Lung Cancer? Lessons from Current Evidence and New Hypotheses. Pharmaceuticals. 2022; 15(7):786.
https://doi.org/10.3390/ph15070786
Chicago/Turabian Style
Barrios-Bernal, Pedro, Zyanya Lucia Zatarain-Barrón, Norma Hernández-Pedro, Mario Orozco-Morales, Alejandra Olivera-Ramírez, Federico Ávila-Moreno, Ana Laura Colín-González, Andrés F. Cardona, Rafael Rosell, and Oscar Arrieta.
2022. "Will We Unlock the Benefit of Metformin for Patients with Lung Cancer? Lessons from Current Evidence and New Hypotheses" Pharmaceuticals 15, no. 7: 786.
https://doi.org/10.3390/ph15070786
APA Style
Barrios-Bernal, P., Zatarain-Barrón, Z. L., Hernández-Pedro, N., Orozco-Morales, M., Olivera-Ramírez, A., Ávila-Moreno, F., Colín-González, A. L., Cardona, A. F., Rosell, R., & Arrieta, O.
(2022). Will We Unlock the Benefit of Metformin for Patients with Lung Cancer? Lessons from Current Evidence and New Hypotheses. Pharmaceuticals, 15(7), 786.
https://doi.org/10.3390/ph15070786
